top of page
  • Derek Boyd

The Week In Psychedelics News: March 10 Through March 16, 2024

Welcome to the first edition of PPS’s Psychedelic News! Our blog team searches for the biggest stories in the world of psychedelics for the week and posts a quick summary here with a link to the full story so you can get up to date on what’s happening in the world of psychedelics. Thanks for checking us out!

Promising News About The Therapeutic Value Of Ibogaine

Photo Credit: Scamperdale

According to the Washington Post, A Stanford University study being conducted in Mexico on the therapeutic effects of the psychedelic drug ibogaine for addiction, depression, anxiety, and PTSD is showing promising results. One of the study’s participants, a Navy Special Ops veteran, stated that extract from the African shrub helped him deal with combat-derived PTSD and that the compound helped shift his consciousness, “into a higher gear.”

Many other advocates feel ibogaine could be useful in treating opioid addiction in hard-hit states such as Ohio, and some big names in sports, entertainment, finance, and technology are putting their names behind this promising entheogen. Supporters include; singer/songwriter Melissa Etheridge and NBA star Lamar Odom.

Because ibogaine has been illegal since 1967, many Americans have been traveling to Mexico to experience its therapeutic effects and treat everything from Cocaine addiction to severe depression. 

Stanford can study the therapeutic value of ibogaine thanks to funding from billionaire venture capitalist Steve Jurvetson and his wife, Genevieve, along with grants from the Sergey Brin (Google Co-founder) Family Foundation. Because ibogaine is a Schedule 1 substance, very few studies have been conducted on its effectiveness in the US, so this is very promising. It’s also important to note that while preliminary results may be promising, ibogaine may not be a magic bullet and other therapies may be required to maintain freedom from addiction and mental illness.

NYSE Traded Psychedelics Company Receives Fast-Tracked Review Pathway From The FDA For Major Depressive Disorder Therapy

Cybin, a Wall Street-traded biopharmaceutical company announced that it will receive a Breakthrough Therapy Designation (BTD) from the FDA for its psychedelic-based treatment for major depressive disorder (MDD). This means that the FDA has found there’s a significant need for treatment options for MDD so they’re accelerating the review process for Cybin’s drug. So far, study results have been promising, with 75% of patients experiencing positive effects and 60% experiencing remission after just two doses.

Clinical Trial of LSD Shows “Immediate And Lasting Relief From Anxiety”

Credit: cosmicgrooveart

In similar news to Cybin’s BTD, another biopharmaceutical, Mind Medicine Inc. company has received a BTD for an LSD-based drug called MM120. This drug has shown efficacy in treating generalized anxiety disorder (GAD), with a 48% remission rate 12 weeks after receiving a single dose. This is even more impressive when you consider that patients weren’t supported with any type of psychotherapy. 

GAD is the most common mental ailment in the United States, affecting over 40 million adults according to the Anxiety and Depression Association of America and effective treatment with today’s standard of care for GAD has been hit and miss. Current medications take time to work, don’t work for everyone, and patients eventually develop a tolerance, so such a long-lasting treatment is a promising development for anxiety sufferers.

This study marks the first time LSD has been studied in a clinical setting since Timothy Leary and Richard Alpert (Ram Daas) were fired from Harvard for giving psychedelics to undergrads in 1963. The US outlawed LSD research shortly thereafter in 1968, and the Controlled Substances Act of 1970 made all psychedelics Schedule 1 drugs, at the same level as heroin, and deemed to have no therapeutic value. 

U.S. Congress Will Hold Hearing On Psychedelics And Medical Marijuana For Veterans


The House Veterans Affairs Health Subcommittee will have hearings on two bills that promote medical cannabis and psychedelics on March 21, 2024. The first bill, the Veterans Cannabis Analysis, Research, and Effectiveness (CARE) Act, sponsored by Mariannette Miller-Meeks (R-IA), is aimed at using cannabis to treat PTSD and other conditions in vets. The second bill is aimed at allowing the VA to add psychedelic medicines to its formulary within 180 days of FDA approval. As of now, there are no psychedelic drugs that are FDA-approved for medical use, but bills like this could help pave the way.

58 views0 comments


bottom of page